Related Experiment Video
Updated: Aug 31, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
[Progress of Non-Factor Products in Hemophilia Treatment--Review]
Jing-Jing Liang1, Lin-Hua Yang2
1Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Abstract:
Traditional replacement therapy is the main treatment method of hemophilia, while inhibitor generation makes replacement therapy ineffective. The emergence of non-factor therapy brings new hope for the treatment of patients with inhibitor. Non-factor products mainly achieve therapeutic purpose by imitating the function of coagulation factor Ⅷ, inhibiting the function of anti-tissue factor pathway inhibitors, the expression of antithrombin mRNA, and the function of activated protein C. This paper reviews the latest research progress of non-factor products in the treatment of hemophilia.

